Perrigo Completes $1.5bn Rx Divestment

New Owner Altaris Capital Rebrands Prescription Unit As Padagis

 
• By Dave Wallace

Perrigo has completed the divestment of its Rx prescription generics business to Altaris Capital Partners for $1.55bn, completing its transition to become a self-care consumer healthcare-focused company. Altaris has rebranded the unit as Padagis.

Jigsaw Puzzle Final Piece
Closing the deal completes Perrigo’s transformation into a self-care company • Source: Alamy

More from Deals

More from Business